#USA #Envista Holdings #Brea #Dental Products #NVST

Insights into Envista Holdings Corporation's Q1 2025 Results

Envista Holdings Corporation (NYSE: NVST) has revealed its financial performance for the first quarter ending March 28, 2025. According to Paul Keel, CEO of Envista, the results align with expectations, showcasing the progress made since the latter half of 2024. Throughout the quarter, the company concentrated on strengthening its growth, operations, and workforce initiatives.

Q1 Financial Highlights

In the first quarter of 2025, Envista achieved impressive sales of $617 million, with core sales growing by 0.2% compared to the same period last year. The net income reached $18 million, and the adjusted EBITDA margin stood at a consistent 12.8%. Notably, the equipment and consumables sector experienced positive growth, compensating for the ongoing challenges faced in the diagnostics market.

However, the specialty products and technologies segment saw a slight contraction, where growth from Nobel Biocare and Spark clear aligners was overshadowed by a drop in orthodontic sales in China, likely due to preparations for Volume-Based Pricing (VBP).

Earnings per share (EPS) reported at $0.10, exceeding forecasts, with adjusted EPS at $0.24.

Detailed Financial Metrics:

• - Net Income: $18 million (down from $24 million last year)
• - Adjusted Net Income: $42 million (down from $46 million)
• - Diluted EPS: $0.10 (compared to $0.14 in Q1 2024)
• - Adjusted EBITDA: $79 million (down from $87 million last year)

Operational Highlights

Envista's operations reflected broad-based contributions from its key segments:

• - Consumables Growth: The Consumables division, alongside Nobel Biocare and Spark, indicated significant advancements.
• - Operational Efficiency: Continuous improvements in gross margins for Spark were observed, along with high customer service levels and overall good productivity metrics.
• - Employee Engagement: Enhanced employee engagement and retention efforts were also noted as part of the ongoing people strategy.

Cash Flow Insights

Operating cash flow for Q1 2025 reported at zero, contrasting significantly with $40 million from the first quarter of FY 2024. The free cash flow registered a deficit of $5 million compared to a positive $29 million in the same period last year. During the quarter, Envista repurchased approximately 1.1 million shares for about $19 million, maintaining a repurchase capacity of $231 million.

Looking Ahead

Envista plans to uphold its full-year guidance for 2025, aiming for:

• - Core Sales Growth: Targeting 1% to 3%
• - Adjusted EBITDA Margins: Approximately 14%
• - Adjusted EPS: Expected between $0.95 and $1.05

The company is committed to transparently communicating its quarterly trends and providing a comprehensive outlook for 2025 during an upcoming investor conference call scheduled for today at 2:00 PM PT.

For more details about Envista Holdings and its offerings, interested parties can visit its official website at www.envistaco.com. The company intends to continue facilitating superior patient care through innovative dental solutions and technologies.

Company Overview

Envista is a prominent global entity comprising over 30 well-established dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr. The company is dedicated to enhancing patient care through its extensive product offerings for various dental procedures and technological needs, contributing significantly to the advancement of the dental industry. Armored by a robust operational strategy centered around the Envista Business System (EBS), the leadership team is positioned to address the diverse needs of dental professionals globally.